ahlam1399
02-25-2016, 03:22 PM
AstraZeneca?s $4 billion Acerta deal endorsed by orphan drug status
LONDON (Reuters) - AstraZeneca's bold move to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion in December has been vindicated, at least in part, by the award of special "orphan" status to the key experimental drug involved.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4dd744d0/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=nGRAZrh9sgA:zcE-I-4eM7I:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=nGRAZrh9sgA:zcE-I-4eM7I:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=nGRAZrh9sgA:zcE-I-4eM7I:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=nGRAZrh9sgA:zcE-I-4eM7I:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=nGRAZrh9sgA:zcE-I-4eM7I:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/nGRAZrh9sgA
LONDON (Reuters) - AstraZeneca's bold move to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion in December has been vindicated, at least in part, by the award of special "orphan" status to the key experimental drug involved.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4dd744d0/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=nGRAZrh9sgA:zcE-I-4eM7I:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=nGRAZrh9sgA:zcE-I-4eM7I:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=nGRAZrh9sgA:zcE-I-4eM7I:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=nGRAZrh9sgA:zcE-I-4eM7I:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=nGRAZrh9sgA:zcE-I-4eM7I:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/nGRAZrh9sgA